Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cubist Makes Attractive Bid for Adolor

Investment View of the Proposed Acquisition

Cubist announced today that it had signed a definitive agreement to acquire Adolor.

 

Adolor has been…
Read more…

Cubist Makes Attractive Takeover Bid for Adolor (ADLR, $1.91)

Investment View of the Proposed Acquisition
Cubist announced today that it had signed a definitive agreement to acquire Adolor.
Adolor has been…
Read more…

Check with Adolor Management on Entereg Marketing Transition and Progress of Partnering Discussions on ADL 5945 (ADLR, $2.05)

Investment Thesis
I upgraded Adolor to a BUY after the company announced that it had reacquired all rights to Entereg from…
Read more…

Phase II Data for ADL 5945 in Opiod Induced Constipation is Excellent (ADLR, $2.23)

On a first quick review of the data from the phase II trial of ADL 5945 in chronic non-cancer pain…
Read more…

Prospects for Entereg May Justify $4.50 Price Target for 2013 (ADLR, $2.20)

Overview
I recommended the purchase of Adolor in a report issued on June 19. This followed my initiation report of February…
Read more…

Upgrading to Buy Based On Regaining Glaxo's Rights in Entereg (ADLR, $1.65)

Investment Thesis
Adolor has gained back Glaxo’s rights to Entereg (alvimopan) in a transaction that I regard as a highly positive,…
Read more…

Analysis of Adolor's 1Q, 2011 and A Look Forward (ADLR, $1.39)

Entereg Results in the Quarter Were Excellent
Entereg achieved sales of $7.5 million which was an increase of 41% from 1Q,…
Read more…

Initial Report on Adolor (ADLR, $1.38)

Adolor as a Stock

While I am currently neutral on Adolor, it is a stock that I am watching closely. To…
Read more…